Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Peak Bio is a clinical-stage biopharmaceutical company developing innovative cancer, inflammatory, and rare disease therapeutics. Its core focus is on antibody-drug conjugates (ADCs) utilizing proprietary payload platforms, including novel toxins targeting RNA splicing and immune modulation. The company aims to create targeted, differentiated treatments with improved efficacy and safety, leveraging advanced antibody technologies and strategic partnerships to address unmet medical needs in oncology and rare diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.